Neuland Laboratories Q2 FY27: revenue down 12.6% to ₹450 Cr, net profit down 46.7% to ₹52 Cr
Results · Finvezto · 3 Nov 2026 · Neuland Laboratories (NEULANDLAB)
Results Q2 FY27, ₹ Cr
| Q2 FY27 | ₹ Cr | QoQ | YoY |
|---|---|---|---|
| Revenue | 450 | -29.9% | -12.6% |
| Operating profit | 98 | -56.2% | -37.2% |
| Net profit | 52 | -65.1% | -46.7% |
| Operating margin | 21.7% | -13.0 pp | -8.5 pp |
| Net margin | 11.5% | -11.6 pp | -7.3 pp |
Key points
- Neuland Laboratories reported standalone total income of Rs 457.2 crore for Q2 FY27, down 11.4% YoY, with EBITDA falling 33.4% to Rs 104.6 crore and profit after tax declining 47.0% to Rs 51.1 crore. NSE filing
- Operating margins were impacted by operating deleverage, while the company inaugurated a new peptide facility and acquired 134 acres of land in Kakinada for long-term expansion. NSE filing
- Q2 total income was Rs.457.2 Crores against Rs.516.1 Crores a year ago, with EBITDA of Rs.104.6 Crores at a 22.9% margin versus 30.4%, and profit after tax of Rs.51.1 Crores versus Rs.96.5 Crores. Earnings call
- H1 FY27 total income stood at Rs.1107.2 Crores versus Rs.816.7 Crores in H1 FY26, with first-half capex outflow of Rs.261 Crores, free cash flow of Rs.99 Crores and net debt of negative Rs.208 Crores. Earnings call
What to watch
- Management on fy27 and fy28 growth: As we enter the second half of the year, expectations of growth remain intact for this as well as the following financial year.
- Management on peptide ppq revenues: Maybe 6 to 9 months away, Chirag, to see like PPQ-related revenues coming from peptides.
- Operating margin over the last 4 quarters (Dec 25, Mar 26, Jun 26, Sep 26): 17.5%, 39.6%, 34.7%, 21.7%.
- Net profit over the last 4 quarters (Dec 25, Mar 26, Jun 26, Sep 26), ₹ Cr: 41, 213, 148, 52.
Links
NSE filing (PDF) · Company page · Results tracker
Anand Ganapathy K | SEBI Registered Research Analyst | INH000016630.